Although epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are very effective against EGFR-mutant lung cancer, resistance to these drugs occurs within approximately 1 year, on average [9, 10]. Here, EGFR is linked to lung carcinoma.